Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 701 - 800
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 701 | 26853201 |
US |
40 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 702 | 26853209 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 703 | 26853391 |
US |
51 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 704 | 26853409 |
US |
77 | 2 |
Pollakiuria, Bladder discomfort, Sleep disorder due to a general medical condition, Injection site pain, Dermatitis atopic, Pruritus, Skin exfoliation, Erythema, Rash, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, UMECLIDINIUM, LORAZEPAM, MAGNESIUM, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, MUPIROCIN, MUPIROCIN CALCIUM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PREDNISONE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 705 | 26853756 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 706 | 26853775 |
US |
34 | 2 |
Pruritus, Dry skin, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 707 | 26854131 |
US |
24 | 2 |
Rhinitis allergic, Dermatitis atopic, Asthma, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 708 | 26854139 |
US |
1 | |
Blister, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 709 | 26854145 |
US |
9 | 1 |
Abnormal behaviour, Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 710 | 26854166 |
US |
1 | |
Dermatitis atopic, Dizziness, Injection site pain, |
||||
DUPILUMAB, |
||||
| 711 | 26854500 |
US |
32 | 1 |
Dust allergy, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 712 | 26854545 |
US |
60 | 1 |
Neck pain, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 713 | 26854890 |
US |
3 | 2 |
Dermatitis atopic, Infection, |
||||
DUPILUMAB, |
||||
| 714 | 26854910 |
US |
36 | 2 |
Skin haemorrhage, Pruritus, Scratch, Dermatitis atopic, |
||||
DUPILUMAB, CLINDAMYCIN HYDROCHLORIDE, FLUCONAZOLE, METRONIDAZOLE, METRONIDAZOLE TOPICAL, |
||||
| 715 | 26854915 |
US |
11 | 2 |
Dermatitis atopic, Erythema, Pruritus, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 716 | 26855260 |
US |
2 | |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 717 | 26855289 |
US |
57 | 2 |
Dermatitis atopic, Pruritus, Rash macular, Skin burning sensation, |
||||
DUPILUMAB, |
||||
| 718 | 26855295 |
US |
43 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 719 | 26855299 |
US |
57 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 720 | 26855300 |
US |
5 | 2 |
Dermatitis atopic, Rash pruritic, |
||||
DUPILUMAB, |
||||
| 721 | 26855315 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 722 | 26855607 |
US |
2 | |
Dermatitis atopic, Eczema, Erythema, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 723 | 26855618 |
US |
53 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 724 | 26855622 |
US |
2 | |
Dermatitis atopic, Allergy to chemicals, Vomiting, Dizziness, Tinnitus, Injection site pain, |
||||
DUPILUMAB, |
||||
| 725 | 26855628 |
US |
35 | 2 |
Sleep disorder, Dry skin, Pruritus, Skin exfoliation, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 726 | 26856236 |
US |
26 | 1 |
Scratch, Erythema, Pruritus, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 727 | 26856238 |
US |
81 | 1 |
Peripheral swelling, Pain in extremity, Dermatitis atopic, Skin lesion, |
||||
DUPILUMAB, |
||||
| 728 | 26856295 |
US |
49 | 1 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 729 | 26856373 |
US |
74 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
TRALOKINUMAB-LDRM, |
||||
| 730 | 26856378 |
US |
57 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 731 | 26856449 |
US |
54 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 732 | 26856471 |
US |
45 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 733 | 26856703 |
US |
24 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 734 | 26856719 |
US |
47 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 735 | 26856729 |
US |
67 | 2 |
Dermatitis atopic, Pruritus, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 736 | 26856876 |
US |
71 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 737 | 26857241 |
US |
39 | 2 |
Sleep disorder due to a general medical condition, Injection site pruritus, Diarrhoea, Dermatitis atopic, Rash, Discomfort, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 738 | 26846784 |
US |
26 | 1 |
Alopecia, Dermatitis atopic, Skin hyperpigmentation, Skin atrophy, Dry skin, |
||||
DUPILUMAB, |
||||
| 739 | 26846909 |
US |
41 | 1 |
Seizure, Insomnia, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 740 | 26846926 |
US |
2 | |
Dermatitis atopic, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, DUPILUMAB, DESOGESTREL AND ETHINYL ESTRADIOL, LORATADINE, LORATADINE TABLET, ESCITALOPRAM, LISINOPRIL, MONTELUKAST SODIUM, |
||||
| 741 | 26846936 |
US |
36 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, PREDNISONE, DULOXETINE HYDROCHLORIDE, DULOXETINE, LORATADINE, LORATADINE TABLET, GABAPENTIN, BUSPIRONE HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, |
||||
| 742 | 26847128 |
US |
20 | 2 |
Dry skin, Skin exfoliation, Pruritus, Injection site erythema, Injection site bruising, Dermatitis atopic, |
||||
DUPILUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, EPINEPHRINE, MONTELUKAST SODIUM, LEVOCETIRIZINE DIHYDROCHLORIDE, ROFLUMILAST, |
||||
| 743 | 26847132 |
US |
30 | 2 |
Dermatitis atopic, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 744 | 26847347 |
US |
45 | 2 |
Dermatitis atopic, Seasonal allergy, |
||||
DUPILUMAB, |
||||
| 745 | 26847582 |
US |
25 | 2 |
Eyelid irritation, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 746 | 26847583 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 747 | 26847642 |
US |
36 | 1 |
Sleep disorder due to a general medical condition, Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, ALBUTEROL SULFATE, ALBUTEROL, OLANZAPINE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, |
||||
| 748 | 26847649 |
US |
54 | 2 |
Spinal operation, Dermatitis atopic, |
||||
DUPILUMAB, NORTRIPTYLINE HYDROCHLORIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PREGABALIN, SUMATRIPTAN SUCCINATE, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, LORATADINE, LORATADINE ORAL, TIRZEPATIDE, AZATHIOPRINE, |
||||
| 749 | 26847722 |
US |
70 | 1 |
Pruritus, Extra dose administered, Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 750 | 26847883 |
US |
2 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, LEBRIKIZUMAB-LBKZ, |
||||
| 751 | 26848123 |
US |
57 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 752 | 26848162 |
US |
32 | 2 |
Blepharospasm, Dermatitis atopic, Increased appetite, Stress, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 753 | 26848218 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 754 | 26848251 |
US |
11 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 755 | 26848268 |
US |
43 | 1 |
Dermatitis atopic, Injection site rash, Therapeutic product effect decreased, |
||||
TRALOKINUMAB-LDRM, DUPILUMAB, |
||||
| 756 | 26848369 |
US |
42 | |
Dermatitis atopic, Device malfunction, Product dose omission issue, Off label use, Intentional underdose, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 757 | 26848579 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 758 | 26848591 |
US |
2 | |
Dermatitis atopic, Rash, Erythema, Pruritus, |
||||
DUPILUMAB, |
||||
| 759 | 26848594 |
US |
10 | 2 |
Dermatitis atopic, Erythema, Skin exfoliation, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 760 | 26848605 |
US |
73 | 2 |
Dermatitis atopic, Eczema, |
||||
DUPILUMAB, |
||||
| 761 | 26848612 |
US |
2 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, TIRZEPATIDE, |
||||
| 762 | 26848627 |
US |
1 | |
Dermatitis atopic, Eczema, Drug ineffective, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, TRALOKINUMAB-LDRM, |
||||
| 763 | 26848866 |
US |
23 | 2 |
Dermatitis atopic, Injection site rash, Injection site erythema, |
||||
TRALOKINUMAB-LDRM, |
||||
| 764 | 26848987 |
US |
9 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 765 | 26848991 |
US |
4 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 766 | 26849018 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 767 | 26849236 |
US |
49 | |
Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 768 | 26849402 |
US |
2 | |
Erythema, Pruritus, Skin burning sensation, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 769 | 26849405 |
US |
25 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 770 | 26849775 |
US |
64 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, DELGOCITINIB, |
||||
| 771 | 26849848 |
US |
||
Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 772 | 26849958 |
EU |
69 | 2 |
Dermatitis atopic, Cutaneous lupus erythematosus, Ocular rosacea, Umbilical erythema, Swelling, Skin exfoliation, |
||||
VENETOCLAX, OBINUTUZUMAB, |
||||
| 773 | 26850103 |
US |
61 | 1 |
Dermatitis atopic, Dry skin, Pruritus, |
||||
DUPILUMAB, ALLOPURINOL, AMLODIPINE, |
||||
| 774 | 26850438 |
US |
69 | 1 |
Dermatitis atopic, Therapeutic response decreased, Pruritus, Dermatitis, Sinusitis, Adenoiditis, Rhinorrhoea, Oropharyngeal pain, Hypersensitivity, |
||||
DUPILUMAB, |
||||
| 775 | 26851073 |
US |
23 | 2 |
Seasonal allergy, Dermatitis atopic, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 776 | 26851370 |
US |
1 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 777 | 26851627 |
US |
33 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, Product prescribing error, |
||||
DUPILUMAB, |
||||
| 778 | 26851632 |
US |
13 | 2 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 779 | 26851633 |
US |
18 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 780 | 26852122 |
CA |
30 | 1 |
Dermatitis, Dermatitis atopic, Hidradenitis, Skin disorder, |
||||
UPADACITINIB, UPADACITINIB, TAZAROTENE, |
||||
| 781 | 26845911 |
US |
14 | 1 |
Injection site pain, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 782 | 26845917 |
US |
61 | 1 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 783 | 26845959 |
US |
69 | 2 |
Rhinitis allergic, Condition aggravated, Dermatitis atopic, Skin exfoliation, Injection site pain, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 784 | 26845963 |
US |
47 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 785 | 26846061 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 786 | 26846293 |
US |
29 | 2 |
Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 787 | 26846660 |
AU |
1 | |
Latent tuberculosis, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 788 | 26844987 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 789 | 26845060 |
US |
21 | 2 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 790 | 26845216 |
US |
48 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 791 | 26845326 |
US |
1 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 792 | 26845331 |
US |
46 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 793 | 26845337 |
US |
45 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 794 | 26845432 |
US |
80 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 795 | 26845490 |
US |
50 | 2 |
Hepatic enzyme increased, Hypersensitivity, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 796 | 26845496 |
US |
2 | |
Dermatitis atopic, Psoriasis, |
||||
DUPILUMAB, |
||||
| 797 | 26845501 |
US |
52 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 798 | 26845504 |
US |
81 | 1 |
Dermatitis atopic, Arthralgia, |
||||
DUPILUMAB, |
||||
| 799 | 26839671 |
US |
26 | 2 |
Sleep disorder due to a general medical condition, Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 800 | 26839824 |
US |
1 | |
Dermatitis atopic, Rash pruritic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30